BRPI1010896A2 - benzoxazepinas como inibidores de pi3k/mtor e métodos de seus usos e fabricação - Google Patents
benzoxazepinas como inibidores de pi3k/mtor e métodos de seus usos e fabricaçãoInfo
- Publication number
- BRPI1010896A2 BRPI1010896A2 BRPI1010896A BRPI1010896A BRPI1010896A2 BR PI1010896 A2 BRPI1010896 A2 BR PI1010896A2 BR PI1010896 A BRPI1010896 A BR PI1010896A BR PI1010896 A BRPI1010896 A BR PI1010896A BR PI1010896 A2 BRPI1010896 A2 BR PI1010896A2
- Authority
- BR
- Brazil
- Prior art keywords
- benzoxazepines
- pi3k
- manufacture
- methods
- mtor inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21714609P | 2009-05-26 | 2009-05-26 | |
| PCT/US2010/036032 WO2010138487A1 (en) | 2009-05-26 | 2010-05-25 | BENZOXAZEPINES AS INHIBITORS OF PI3K/m TOR AND METHODS OF THEIR USE AND MANUFACTURE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1010896A2 true BRPI1010896A2 (pt) | 2019-09-24 |
Family
ID=42634933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1010896A BRPI1010896A2 (pt) | 2009-05-26 | 2010-05-25 | benzoxazepinas como inibidores de pi3k/mtor e métodos de seus usos e fabricação |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8637499B2 (pt) |
| EP (1) | EP2435426B8 (pt) |
| JP (1) | JP2012528165A (pt) |
| KR (1) | KR20120087808A (pt) |
| CN (1) | CN102459248A (pt) |
| AR (1) | AR076922A1 (pt) |
| AU (1) | AU2010254200A1 (pt) |
| BR (1) | BRPI1010896A2 (pt) |
| CA (1) | CA2763008A1 (pt) |
| ES (1) | ES2425091T3 (pt) |
| HK (1) | HK1168349A1 (pt) |
| IL (1) | IL216473A0 (pt) |
| MX (1) | MX2011012584A (pt) |
| NZ (1) | NZ596552A (pt) |
| WO (1) | WO2010138487A1 (pt) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| CN104926815B (zh) | 2008-01-04 | 2017-11-03 | 英特利凯恩有限责任公司 | 某些化学实体、组合物和方法 |
| CA2763099A1 (en) * | 2009-05-22 | 2010-11-25 | Exelixis, Inc. | Benzoxazepines based p13k/mt0r inhibitors against proliferative diseases |
| US9670212B2 (en) | 2010-09-14 | 2017-06-06 | Exelixis, Inc. | Inhibitors of PI3K-delta and methods of their use and manufacture |
| EP2624696B1 (en) | 2010-10-06 | 2016-12-21 | Glaxosmithkline LLC | Benzimidazole derivatives as pi3 kinase inhibitors |
| EP2640367A2 (en) * | 2010-11-15 | 2013-09-25 | Exelixis, Inc. | Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture |
| EP2640366A2 (en) * | 2010-11-15 | 2013-09-25 | Exelixis, Inc. | Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture |
| EA201390755A1 (ru) * | 2010-11-24 | 2013-11-29 | Экселиксис, Инк. | БЕНЗОКСАЗЕПИНЫ КАК ИНГИБИТОРЫ PI3K/mTOR И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ И ПРОИЗВОДСТВА |
| EP2643316A2 (en) * | 2010-11-24 | 2013-10-02 | Exelixis, Inc. | Benzoxazepines as inhibitors of p13k/mtor and methods of their use and manufacture |
| BR112013017670B1 (pt) | 2011-01-10 | 2022-07-19 | Infinity Pharmaceuticals, Inc | Processos de preparação de isoquinolinonas e formas sólidas de isoquinolinonas |
| US9127000B2 (en) | 2011-02-23 | 2015-09-08 | Intellikine, LLC. | Heterocyclic compounds and uses thereof |
| RU2456287C1 (ru) * | 2011-05-20 | 2012-07-20 | Николай Филиппович Савчук | Стимуляторы секреции инкретиновых гормонов, способы их получения и применения |
| BR112014010492A2 (pt) | 2011-11-01 | 2017-04-25 | Exelixis Inc | n-(3-{[(3-{[2-cloro-5-(metóxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-metilalaninamida como inibidor de fosfatidilinositol 3-cinase para o tratamento de malignidades linfoproliferativas |
| FR2986232B1 (fr) * | 2012-01-26 | 2014-02-14 | Sanofi Sa | Derives heterocycliques bicycliques, leur preparation et leur application en therapeutique |
| US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
| FR2994572B1 (fr) * | 2012-08-17 | 2015-04-17 | Centre Nat Rech Scient | Pyrido[3,2-d]pyrimidines trisubstituees, leurs procedes de preparation et leurs utilisation en therapeutique |
| US10273243B2 (en) | 2013-03-14 | 2019-04-30 | The Trustees Of Columbia University In The City Of New York | 4-phenylpiperidines, their preparation and use |
| WO2014151959A1 (en) | 2013-03-14 | 2014-09-25 | The Trustees Of Columbia University In The City Of New York | N-alkyl-2-phenoxyethanamines, their preparation and use |
| US9944644B2 (en) * | 2013-03-14 | 2018-04-17 | The Trustees Of Columbia University In The City Of New York | Octahydropyrrolopyrroles their preparation and use |
| WO2014152018A1 (en) | 2013-03-14 | 2014-09-25 | The Trustees Of Columbia University In The City Of New York | Octahydrocyclopentapyrroles, their preparation and use |
| WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| EP3137168B1 (en) | 2014-04-30 | 2022-01-05 | The Trustees of Columbia University in the City of New York | Substituted 4-phenylpiperidines, their preparation and use |
| CN107995911B (zh) * | 2015-07-02 | 2020-08-04 | 豪夫迈·罗氏有限公司 | 苯并氧氮杂*噁唑烷酮化合物及其使用方法 |
| CN108884054B (zh) * | 2015-11-30 | 2022-08-02 | 儿童医学中心公司 | 用于治疗增殖性疾病的化合物 |
| WO2017205536A2 (en) * | 2016-05-24 | 2017-11-30 | Genentech, Inc. | Therapeutic compounds and uses thereof |
| MX2018016227A (es) | 2016-06-24 | 2019-07-08 | Infinity Pharmaceuticals Inc | Terapias de combinacion. |
| AU2018263886C1 (en) * | 2017-05-02 | 2022-12-22 | Revolution Medicines, Inc. | Rapamycin analogs as mTOR inhibitors |
| WO2019055877A1 (en) | 2017-09-15 | 2019-03-21 | Forma Therapeutics, Inc. | TETRAHYDROIMIDAZO QUINOLINE COMPOSITIONS AS INHIBITORS OF CBP / P300 |
| IL278335B1 (en) | 2018-05-01 | 2024-05-01 | Revolution Medicines Inc | C26-linked rapamycin analogs as MTOR inhibitors |
| IL279734B1 (en) | 2018-06-29 | 2024-07-01 | Forma Therapeutics Inc | CREB-binding protein (CBP) inhibition |
| WO2020048831A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | 5-aryl-3,9-diazaspiro[5.5]undecan-2-one compounds |
| WO2020048830A1 (en) * | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | 5-aryl-3,9-diazaspiro[5.5]undecan-2-one compounds |
| WO2020048828A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Pharma Aktiengesellschaft | 5-heteroaryl-3,9-diazaspiro[5.5]undecane compounds |
| CN111297872B (zh) * | 2020-03-02 | 2021-01-12 | 牡丹江医学院 | 一种治疗慢性萎缩性胃炎的药物及其制备方法 |
| US11795168B2 (en) | 2020-09-23 | 2023-10-24 | Forma Therapeutics, Inc. | Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP) |
| US11801243B2 (en) | 2020-09-23 | 2023-10-31 | Forma Therapeutics, Inc. | Bromodomain inhibitors for androgen receptor-driven cancers |
| CN114105863B (zh) * | 2021-12-07 | 2023-11-28 | 江苏汉拓光学材料有限公司 | 酸扩散抑制剂、含酸扩散抑制剂的化学放大型光刻胶及其制备与使用方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4102103A1 (de) | 1991-01-25 | 1992-08-20 | Bayer Ag | Substituierte benzoxazepine und benzthiazepine, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln |
| US5272158A (en) | 1991-10-29 | 1993-12-21 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| WO1996026190A1 (en) * | 1995-02-22 | 1996-08-29 | Smithkline Beecham Corporation | Integrin receptor antagonists |
| US6011029A (en) * | 1996-02-26 | 2000-01-04 | Bristol-Myers Squibb Company | Inhibitors of farnesyl protein transferase |
| AU6935800A (en) | 1999-08-27 | 2001-03-26 | Procter & Gamble Company, The | Controlled availability of formulation components, compositions and laundry methods employing same |
| TR200200471T2 (tr) | 1999-08-27 | 2002-05-21 | The Procter & Gamble Company | Kararlı formülasyon komponentleri, bunların kullanıldığı terkipler ve çamaşır yıkama metodları |
| BR0013610A (pt) | 1999-08-27 | 2002-07-16 | Procter & Gamble | Componentes de formulções de ação rápida,composições e métodos para lavar roupa empregando os mesmos |
| BR0013616B1 (pt) | 1999-08-27 | 2011-12-27 | composiÇço de alvejamento e composto catalisador orgÂnico de lavanderia. | |
| WO2002051232A2 (en) * | 2000-12-27 | 2002-07-04 | Actelion Pharmaceuticals Ltd. | Novel benzazepines and related heterocyclic derivatives |
| US20030114448A1 (en) | 2001-05-31 | 2003-06-19 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| US7196108B2 (en) | 2002-03-08 | 2007-03-27 | Incyte San Diego Inc. | Bicyclic heterocycles for the treatment of diabetes and other diseases |
| CA2510851A1 (en) * | 2002-12-20 | 2004-07-08 | Warner-Lambert Company Llc | Benzoxazines and derivatives thereof as inhibitors of pi3ks |
| US7521457B2 (en) | 2004-08-20 | 2009-04-21 | Boehringer Ingelheim International Gmbh | Pyrimidines as PLK inhibitors |
| JP5497429B2 (ja) | 2007-03-07 | 2014-05-21 | 武田薬品工業株式会社 | ベンゾオキサゼピン誘導体およびその用途 |
| WO2008144483A2 (en) * | 2007-05-18 | 2008-11-27 | Armgo Pharma, Inc. | Agents for treating disorders involving modulation of ryanodine receptors |
| US20110263569A1 (en) | 2007-08-22 | 2011-10-27 | President And Fellows Of Harvard College | Ryanodine channel binders and uses thereof |
| WO2009096631A1 (en) | 2008-01-31 | 2009-08-06 | Industrial Cooperation Foundation Chonbuk National University | Tuber diagnosis device |
| CN101497612A (zh) | 2009-03-03 | 2009-08-05 | 北京华禧联合科技发展有限公司 | 一类新喹诺酮类化合物及其制备与用途 |
| WO2010118208A1 (en) * | 2009-04-09 | 2010-10-14 | Exelixis, Inc. | Benzoxazepin-4- (5h) -yl derivatives and their use to treat cancer |
| CA2763099A1 (en) | 2009-05-22 | 2010-11-25 | Exelixis, Inc. | Benzoxazepines based p13k/mt0r inhibitors against proliferative diseases |
-
2010
- 2010-05-25 WO PCT/US2010/036032 patent/WO2010138487A1/en active Application Filing
- 2010-05-25 JP JP2012513169A patent/JP2012528165A/ja active Pending
- 2010-05-25 CA CA2763008A patent/CA2763008A1/en not_active Abandoned
- 2010-05-25 EP EP10720869.6A patent/EP2435426B8/en active Active
- 2010-05-25 BR BRPI1010896A patent/BRPI1010896A2/pt not_active IP Right Cessation
- 2010-05-25 NZ NZ596552A patent/NZ596552A/en not_active IP Right Cessation
- 2010-05-25 US US13/322,160 patent/US8637499B2/en not_active Expired - Fee Related
- 2010-05-25 CN CN2010800318705A patent/CN102459248A/zh active Pending
- 2010-05-25 KR KR1020117031045A patent/KR20120087808A/ko not_active Application Discontinuation
- 2010-05-25 MX MX2011012584A patent/MX2011012584A/es active IP Right Grant
- 2010-05-25 AU AU2010254200A patent/AU2010254200A1/en not_active Abandoned
- 2010-05-25 ES ES10720869T patent/ES2425091T3/es active Active
- 2010-05-26 AR ARP100101819A patent/AR076922A1/es not_active Application Discontinuation
-
2011
- 2011-11-20 IL IL216473A patent/IL216473A0/en unknown
-
2012
- 2012-09-17 HK HK12109098.8A patent/HK1168349A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP2435426B8 (en) | 2013-07-03 |
| NZ596552A (en) | 2014-02-28 |
| WO2010138487A1 (en) | 2010-12-02 |
| AR076922A1 (es) | 2011-07-20 |
| KR20120087808A (ko) | 2012-08-07 |
| CN102459248A (zh) | 2012-05-16 |
| US20120258953A1 (en) | 2012-10-11 |
| JP2012528165A (ja) | 2012-11-12 |
| MX2011012584A (es) | 2012-02-21 |
| IL216473A0 (en) | 2012-01-31 |
| HK1168349A1 (en) | 2012-12-28 |
| AU2010254200A1 (en) | 2011-12-08 |
| ES2425091T3 (es) | 2013-10-11 |
| EP2435426A1 (en) | 2012-04-04 |
| EP2435426B1 (en) | 2013-05-22 |
| CA2763008A1 (en) | 2010-12-02 |
| US8637499B2 (en) | 2014-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1010896A2 (pt) | benzoxazepinas como inibidores de pi3k/mtor e métodos de seus usos e fabricação | |
| BR112013005523A2 (pt) | composto como inibidores de quinase c-met e seus usos | |
| BR112013011520A2 (pt) | pirazolo piridinas e pirazolo piridinas e seu uso como inibidores de tyk2 | |
| ZA201303858B (en) | Benzoxazepines as inhibitors of p13k/mtor and methods of their use and manufacture | |
| BR112012015827A2 (pt) | novos compostos de pirimidina como inibidores de mtor e p13k | |
| CO6910199A2 (es) | Heterociclilaminas como inhibidores de pi3k | |
| CO6801747A2 (es) | Derivados de pirrolotriazinona como inhibidores de pi3k | |
| ES2598358T8 (es) | Derivados de quinolina como inhibidores de PI3K quinasa | |
| DK3130923T3 (da) | Terapeutiske fremgangsmåder i forbindelse med cancerstamceller | |
| BR112013009496A2 (pt) | artigos absorventes e métodos de fabricação dos mesmos | |
| BR112012000660A2 (pt) | compostos heterociclos e seus usos | |
| CO6920291A2 (es) | 3-pirmidin-4-il-oxazolidin-2-onas como inhibidores de la idhmutante | |
| BR112013014314A2 (pt) | derivados de 6-amino-2-fenilamino-1h-benzimidazol-5-carboxamida e seu uso como inibidores de prostaglandina e2 sintase-1 microssômicas | |
| BR112012001325A2 (pt) | tratamento de distúrbios do fígado com inibidaores de pi3k | |
| ZA201308109B (en) | Tissue repair devices of rapid therapeutic absorbency | |
| BR112013007499A2 (pt) | piridazinonas - métodos de criação e usos | |
| CO6870033A2 (es) | Compuestos terapéuticos y métodos de uso relacionados | |
| BR112012025149A2 (pt) | artigo absorvente e método de fabricação de um artigo absorvente | |
| BR112013016030A2 (pt) | compostos e seu uso como inibidores de bace | |
| BR112013026298A2 (pt) | inibidores de micro-rna e seus usos em doenças | |
| BRPI0921862A2 (pt) | inibidores de raf e seus usos | |
| UY33155A (es) | Indolil-piperidinil bencilaminas como inhibidores de beta-triptasa | |
| BR112012018810A2 (pt) | método de fabricação de um artigo absorvente do tipo calça | |
| DK3222280T3 (da) | Forøgelse af lægemiddelbiotilgængelighed i naltrexonbehandling | |
| BR112013025721A2 (pt) | métodos de fabricação de elementos absorventes volumosos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |